First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension

Riociguat has been approved for use in adults with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension. No clinical data on its therapeutic use in children with PAH are currently available. We report the case of a now four-year-old boy who initially presented at th...

Descripción completa

Detalles Bibliográficos
Autores principales: Spreemann, Till, Bertram, Harald, Happel, Christoph M., Kozlik-Feldmann, Rainer, Hansmann, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731721/
https://www.ncbi.nlm.nih.gov/pubmed/29099661
http://dx.doi.org/10.1177/2045893217743123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5731721/
https://www.ncbi.nlm.nih.gov/pubmed/29099661
http://dx.doi.org/10.1177/2045893217743123

Ejemplares similares